最新ニュース BeiGene (NASDAQ:BGNE) 株価情報

BeiGene

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

Large Cap

News

Movers

APTV

BGNE

BIRK

MRNA

POOL

先週の株価下落率上位10社に名を連ねたのは以下の銘柄だ。投資家はこれらの銘柄を保有しているだろうか？

米製薬大手モデルナ　米国市場を牽引

BeiGene, Ltd. - American Depositary Shares

BeiGene Ltd

Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) reported its Q3 earnings results on Tuesday, December 3, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Salesforce missed estimated earnings by -1.0%, reporting an EPS of $2.41 versus an estimate of $2.44.
Revenue was up $724.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
The company beat on EPS by $0.45 in the last quarter, resulting in a 1.0% drop share price change the following day.
Here's a look at Salesforce's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.11</td>
<td>2.37</td>
<td>2.26</td>
<td>1.88</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.56</td>
<td>2.44</td>
<td>2.29</td>
<td>2.11</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>8.28B</td>
<td>9.15B</td>
<td>9.23B</td>
<td>7.95B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>9.32B</td>
<td>9.13B</td>
<td>9.29B</td>
<td>8.72B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Salesforce <a href="https://www.benzinga.com/quote/CRM/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Salesforce Earnings Review: Q3 Summary

Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) released its Q3 earnings on Tuesday, December 3, 2024 at 04:01 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Okta beat estimated earnings by 16.0%, reporting an EPS of $0.67 versus an estimate of $0.58.
Revenue was up $81.00 million from the same period last year.
<h3>Historical Earnings Summary</h3>
In the previous quarter, the company beat on EPS by $0.11, resulting in a 18.0% drop change in the share price the following day.
Here's a look at Okta's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.61</td>
<td>0.54</td>
<td>0.51</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.72</td>
<td>0.65</td>
<td>0.63</td>
<td>0.44</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>632.94M</td>
<td>604.34M</td>
<td>587.15M</td>
<td>560.77M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>646.00M</td>
<td>617.00M</td>
<td>605.00M</td>
<td>584.00M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Okta <a href="https://www.benzinga.com/quote/OKTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OKTA

Okta Earnings Report: Q3 Overview

Campbell Soup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.87 by 2.3 percent. This is a 2.2 percent decrease over earnings of $0.91 per share from the same period last year. The company reported quarterly sales of $2.77 billion which missed the analyst consensus estimate of $2.80 billion by 0.96 percent. This is a 10.09 percent increase over sales of $2.52 billion the same period last year.

Earnings Beats

Earnings Misses

Campbell Soup Q1 Adj $0.89 Beats $0.87 Estimate, Sales $2.77B Miss $2.80B Estimate

Guidance

Salesforce Sees Q4 Revenue $9.90B-$10.10B, FY25 Revenue $37.80B-$38.00B

Okta Sees FY25 Adj. EPS $2.75-$2.76 Vs $2.61 Est.; Revenue $2.595B-$2.597B Vs 2.563B Est.

Okta Sees Q4 Adj. EPS $0.73-$0.74 Vs $0.67 Est.; Revenue $667M-$669M Vs $650.640M Est.

Black Friday-Cyber Monday recorded GMV growth of 19% in FXN and 21% in orders YoY
VTEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>), the composable and complete commerce platform for premier brands and retailers, announced today that VTEX customers reached a GMV of US$0.9 billion over Black Friday-Cyber Monday week&#x2A;. Compared to 2023, orders increased 21% and GMV grew 19% in FX-neutral and 1% in USD, reflecting the impact of foreign exchange dynamics.
In this edition, across the 43 countries where VTEX operates, the top-performing verticals were Electronics, Home, Furniture &amp; Decoration and Apparel &amp; Accessories achieving GMV FX-neutral growth of 51%, 31% and 19%, respectively.

VTEX

VTEX Announces That VTEX Customers Reached A GMV Of $900M Over Black Friday-Cyber Monday Week, Compared To 2023, Orders Increased 21%

In addition, Janux expects to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions.
The Company intends to use the net proceeds from the offering to advance clinical development of its internal product pipeline and for general corporate purposes.

Offerings

JANX

Janux Therapeutics Commences Underwritten Public Offering Of $300M Of Shares Of Its Common Stock

Poland&#8217;s GDP <a href="https://open.substack.com/pub/europeancapitalinsights/p/polands-gdp-set-for-continued-growth?r=3nmatg&amp;utm_campaign=post&amp;utm_medium=web" rel="nofollow">is set to expand further in 2025</a>, cementing its position as the European Union&#8217;s (EU) fastest-growing economy.
Polish economic growth is projected at 3.7% next year, supported by private consumption and investments, European Commission (EC) <a target="_blank" rel="noreferrer noopener" href="https://economy-finance.ec.europa.eu/economic-surveillance-eu-economies/poland/economic-forecast-poland_en#:~:text=The%20Polish%20economy%20rebounded%20sharply,projected%20in%20the%20Spring%20Forecast">data</a> showed. This expectation expands a strong rebound from 0.2% in 2023 to just over 3% in 2024, according to the forecast on November 15.
A strong financial sector, paired with tight labor markets, has also resulted in significant wage growth, driving increased consumer spending.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fec6b7cfb-0325-4922-9555-47fd1e56f456_1473x371.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fec6b7cfb-0325-4922-9555-47fd1e56f456_1473x371.png" alt="" /></a><figcaption class="wp-element-caption">Real GDP growth, 2021-2026, Source: <a target="_blank" rel="noreferrer noopener" href="https://thedocs.worldbank.org/en/doc/d5f32ef28464d01f195827b7e020a3e8-0500022021/related/mpo-pol.pdf">World Bank</a></figcaption></figure>
&#8220;Poland is one of the great economic growth success stories in the world over the last 30 years,&#8221; Geoff Gottlieb, IMF senior regional representative for Central, Eastern and South-Eastern Europe, <a target="_blank" rel="noreferrer noopener" href="https://x.com/mmpiatkowski/status/1849730926126723474">said</a>.
Poland's GDP outperforms the EU and Germany, Europe's largest economy. The <a href="https://europeancapitalinsights.substack.com/p/european-commission-downgrades-eu" target="_blank" rel="noreferrer noopener nofollow">EC expects the EU GDP to grow</a> by a mere 0.8% this year and 1.5% in 2025. German GDP will contract by 0.1% in 2024 from a 0.1% expansion previously, the second consecutive year of negative growth, the EC said.
<h2 class="wp-block-heading">Consumption-Led Recovery is Driving Poland's GDP</h2>
The IMF staff wrote in a <a target="_blank" rel="noreferrer noopener" href="https://www.imf.org/en/News/Articles/2024/10/17/CS-poland-2024">report</a> published on October 17 that "a consumption-led recovery is underway" in Poland. It added that the "outlook is further supported by recently unlocked NextGen EU Funds (NGEU)."
NextGen EU is a financial package allocated to Poland from the EU&#8217;s &#8220;NextGenerationEU&#8221; recovery plan to help member states recover economically from the COVID-19 pandemic. The package funds investments in green energy, digitalization, and social cohesion.
In the second quarter of 2024, Poland recorded the EU's largest GDP growth at +1.5%.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F04d4e8d4-2aba-4909-8f1e-9c915c29a956_1000x608.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F04d4e8d4-2aba-4909-8f1e-9c915c29a956_1000x608.png" alt="" /></a><figcaption class="wp-element-caption">Quarterly GDP growth by EU country, Q2 2024, Source: <a target="_blank" rel="noreferrer noopener" href="https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Quarterly_national_accounts_-_GDP_and_employment#GDP_growth_by_EU_country">Eurostat</a></figcaption></figure>
<h2 class="wp-block-heading">Investment Key Driver of Poland's GDP Growth</h2>
Poland's corporate sector wages increased by 10.2% year-on-year (YoY) to $2,042 (PLN 8,316.57) in October 2024, following a 10.3% growth in the previous month and beating market expectations of a 10.1% increase.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd0962611-8b4f-487e-865d-dfa4cb85f2ec_1405x968.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd0962611-8b4f-487e-865d-dfa4cb85f2ec_1405x968.png" alt="" /></a><figcaption class="wp-element-caption">Real Wage and Salary Enterprises, %YoY, Source: <a target="_blank" rel="noreferrer noopener" href="https://think.ing.com/snaps/wages-growth-labour-market-poland/">ING</a></figcaption></figure>
The average business employment decreased by 0.5% YoY in October, the same as in September. Despite this setback, Poland&#8217;s labor market remains solid, with unemployment remaining near record lows.
In 2025, EU-funded public investment is also forecasted to be a key driver of Poland's GDP growth. In February, the EU <a target="_blank" rel="noreferrer noopener" href="https://www.gov.pl/web/funds-regional-policy/european-funds-for-poland-unblocked">unblocked</a> around $147 billion (PLN 600 billion) for Poland from the Cohesion Policy and the National Recovery Plan. This is set to stimulate the Polish economy and boost investments.
The funds will help accelerate the green and digital transformation in the economy, increasing energy security and the use of modern technologies.
<h2 class="wp-block-heading">Poland GDP Growth Attracts Foreign Investments</h2>
Poland's strong economic performance has attracted international investments. Microsoft Corp. <a target="_blank" rel="noreferrer noopener" href="https://news.microsoft.com/europe/2023/04/26/microsoft-launches-its-first-datacenter-region-in-poland-bringing-new-opportunities-to-develop-the-digital-economy/">opened in 2023</a> a <a target="_blank" rel="noreferrer noopener" href="https://www.polskieradio.pl/395/7786/Artykul/3157569,US-giant-Microsoft-opens-USD-1-bn-cloud-centre-in-Poland">$1 billion </a>cloud region around Warsaw. It consists of three physical locations with one or more data centers.
"Microsoft's investment in Poland will accelerate our country's transformation into a technology hub for the Central and Eastern European region," Prime Minister Mateusz Morawiecki said at the time.
Microsoft <a target="_blank" rel="noreferrer noopener" href="https://windowsforum.com/threads/microsoft-launches-ai-training-program-in-poland-to-upskill-one-million-individuals.346814/">has also launched</a> an extensive AI training program in Poland, which aims to equip one million individuals with essential AI competencies by the end of 2025.
"Poland found the perfect blend of East and West," Ole Lehmann, the founder of The AI Solopreneur, wrote on <a target="_blank" rel="noreferrer noopener" href="https://x.com/itsolelehmann">X</a>. "They combined: Western innovation without the bureaucracy" and "Eastern work ethic &amp; traditional values without authoritarianism."
<h2 class="wp-block-heading">Challenges to Poland's GDP Growth</h2>
Polish industrial production remained close to stagnant in Q3 (0.6%YoY growth after +0.8%YoY in 2Q24) while construction remained in a recession. A decline in domestic retail trade added further pressure on the economy.
Poland, though, has little room for significant interest rate cuts next year, with wages and consumer prices buoying inflation and economic growth accelerating, the country's deputy central bank chief, Marta Kightley, <a target="_blank" rel="noreferrer noopener" href="https://www.msn.com/en-us/money/markets/poland-has-little-room-for-big-cuts-in-2025-central-banker-says/ar-AA1uRrks?ocid=BingNewsSerp">said</a>. Polish inflation eased in November to 4.6% YoY from 5% YoY in October.
"The decline in inflation in November is a temporary phenomenon," ING <a target="_blank" rel="noreferrer noopener" href="https://think.ing.com/snaps/temporary-decline-in-polands-inflation-in-november/">wrote</a> on November 29. "We project that it will rise in the first quarter of 2025, which will prevent the Monetary Policy Council from beginning its monetary easing cycle until then."
This has significantly slowed real wage growth, which dropped from 8.5% YoY to 6.0%. Higher electricity and gas bills may limit resources available for other household expenditures.
<h2 class="wp-block-heading">What Future Holds for Poland's GDP</h2>
Despite recording the fastest GDP growth in the EU and a record-low unemployment rate, labor shortages paired with low fertility rates and an aging population could pose a future threat to the Polish economy. In the past 30 years, Poland's birth rate decreased by 40%, standing at 1.33 in 2024.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fca5712c9-5ecc-4a94-91d0-33f88f488485_1018x1042.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fca5712c9-5ecc-4a94-91d0-33f88f488485_1018x1042.png" alt="" /></a><figcaption class="wp-element-caption">Crude rates of population change, 2021-2023, Source: <a target="_blank" rel="noreferrer noopener" href="https://ec.europa.eu/eurostat/databrowser/view/demo_gind/default/table?lang=en">Eurostat</a></figcaption></figure>
While the total EU population increased in 2023, the population fell in 7 countries, Latvia (-5.9) and Poland (-3.6), recording some of the highest decreases.
In response to labor market gaps and the need to attract foreign workers, Poland&#8217;s government announced its first comprehensive <a target="_blank" rel="noreferrer noopener" href="https://www.gov.pl/web/premier/uchwala-w-sprawie-przyjecia-dokumentu-odzyskac-kontrole-zapewnic-bezpieczenstwo-kompleksowa-i-odpowiedzialna-strategia-migracyjna-polski-na-lata-2025-2030">migration strategy</a> in October, a step toward addressing demographic challenges.
Many entrepreneurs are concerned that stricter immigration policies will make it harder to hire workers.
Disclaimer:
Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. European Capital Insights is not responsible for any financial decisions made based on the contents of this article. Readers may use this article for information and educational purposes only.
This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content&nbsp;or&nbsp;accuracy.

Emerging Markets

Economics

Poland's GDP Set for Growth in 2025 as EU's Fastest Economy

Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) reported quarterly earnings of $0.67 per share which beat the analyst consensus estimate of $0.58 by 15.52 percent. The company reported quarterly sales of $665.000 million which beat the analyst consensus estimate of $649.702 million by 2.35 percent. This is a 13.87 percent increase over sales of $584.000 million the same period last year.

Okta Q3 2025 Adj. EPS $0.67 Beats $0.58 Estimate, Sales $665.000M Beat $649.702M Estimate

Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) reported quarterly earnings of $2.41 per share which missed the analyst consensus estimate of $2.44 by 1.23 percent. The company reported quarterly sales of $9.440 billion which beat the analyst consensus estimate of $9.345 billion by 1.02 percent. This is a 8.26 percent increase over sales of $8.720 billion the same period last year.

Salesforce Q3 2025 Adj. EPS $2.41 Misses $2.44 Estimate, Sales $9.440B Beat $9.345B Estimate

Clouse Announces Plans to Retire to Join the NFL's Washington Commanders as President
The Campbell's Company (NASDAQ:<a href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) (Campbell's) announced today that its Board of Directors has elected Mick Beekhuizen to succeed Mark Clouse as President and CEO. Beekhuizen has also been elected a Director of the company, both effective Feb. 1, 2025. Until then, Beekhuizen will continue in his role as President, Meals &amp; Beverages.

Management

The Campbell's Company Elects Mick Beekhuizen Chief Executive Officer To Succeed Mark Clouse, Both Effective Feb. 1, 2025

8 analysts have shared their evaluations of Compass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Compass, revealing an average target of $7.81, a high estimate of $9.50, and a low estimate of $6.00. Observing a 18.15% increase, the current average has risen from the previous average price target of $6.61. 
<img src="https://www.benzinga.com/files/images/story/2024/1733259694_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Compass by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$8.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$9.50</td>
<td>$8.50</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$8.50</td>
<td>$8.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$8.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$6.50</td>
<td>$4.40</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$8.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Compass. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Compass compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Compass's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Compass's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COMP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Compass analyst ratings.</a>
<h2>Get to Know Compass Better</h2>
Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.
<h3>Unraveling the Financial Story of Compass</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Compass showcased positive performance, achieving a revenue growth rate of 11.71% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: Compass's net margin excels beyond industry benchmarks, reaching -0.11%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Compass's ROE excels beyond industry benchmarks, reaching -0.41%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Compass's ROA stands out, surpassing industry averages. With an impressive ROA of -0.14%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Compass's debt-to-equity ratio is below the industry average at 1.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

COMP

What Analysts Are Saying About Compass Stock

Throughout the last three months, 10 analysts have evaluated ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated ONEOK and provided 12-month price targets. The average target is $105.5, accompanied by a high estimate of $132.00 and a low estimate of $94.00. Surpassing the previous average price target of $94.78, the current average has increased by 11.31%.
<img src="https://www.benzinga.com/files/images/story/2024/1733259682_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive ONEOK is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$107.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Brian Reynolds</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$132.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$99.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$99.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Sunil Sibal</td>
<td>Seaport Global</td>
<td>Raises</td>
<td>Buy</td>
<td>$103.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$98.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$94.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Robert Kad</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$103.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ONEOK. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ONEOK compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of ONEOK's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ONEOK's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OKE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ONEOK analyst ratings.</a>
<h2>Discovering ONEOK: A Closer Look</h2>
Oneok is a diversified midstream service provider specializing in natural gas gathering, processing, storage, and transportation and natural gas liquids transportation and fractionation. It also operates a refined product and crude oil segment connecting producers, refiners, and consumers. Operations are in the midcontinent, Permian, and Rocky Mountain regions.
<h3>ONEOK: Financial Performance Dissected</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, ONEOK showcased positive performance, achieving a revenue growth rate of 19.91% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: ONEOK's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 13.78%, the company may face hurdles in effective cost management.
Return on Equity (ROE): ONEOK's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 4.12%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.45%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: ONEOK's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.67.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For ONEOK

XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $120.0, a high estimate of $123.00, and a low estimate of $117.00. Observing a 2.56% increase, the current average has risen from the previous average price target of $117.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1733259665_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive XOMA Royalty. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$123.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$123.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$117.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$117.00</td>
<td>$117.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to XOMA Royalty. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of XOMA Royalty compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of XOMA Royalty's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into XOMA Royalty's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/XOMA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on XOMA Royalty analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into XOMA Royalty's Background</h2>
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
<h3>A Deep Dive into XOMA Royalty's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: XOMA Royalty's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -11.57%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: XOMA Royalty's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -2535.56%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): XOMA Royalty's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -20.15%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): XOMA Royalty's ROA stands out, surpassing industry averages. With an impressive ROA of -7.98%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.4, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

XOMA

A Glimpse Into The Expert Outlook On XOMA Royalty Through 4 Analysts

Across the recent three months, 5 analysts have shared their insights on Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Bank OZK, revealing an average target of $49.6, a high estimate of $63.00, and a low estimate of $40.00. Witnessing a positive shift, the current average has risen by 4.2% from the previous average price target of $47.60.
<img src="https://www.benzinga.com/files/images/story/2024/1733259657_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Bank OZK by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jared Shaw</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Matt Olney</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Stephen Scouten</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$63.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$48.00</td>
<td>$49.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bank OZK. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Bank OZK compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Bank OZK's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bank OZK's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OZK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bank OZK analyst ratings.</a>
<h2>Delving into Bank OZK's Background</h2>
Bank OZK is a bank holding company that owns and operates a community bank, Bank of the Ozarks. The bank operates offices in Arkansas, Georgia, Florida, North Carolina, Texas, California, New York and Mississippi. It provides a range of banking services which include deposit services such as checking, savings, money market, time deposit and individual retirement accounts to loan services like real estate, consumer, commercial and industrial loans. Apart from providing traditional banking products and services it also provides treasury management, trust and wealth management, financial planning, online banking and other related services.
<h3>Financial Milestones: Bank OZK's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Bank OZK's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 7.64%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Bank OZK's net margin is impressive, surpassing industry averages. With a net margin of 41.88%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Bank OZK's ROE stands out, surpassing industry averages. With an impressive ROE of 3.43%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Bank OZK's ROA stands out, surpassing industry averages. With an impressive ROA of 0.48%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.12, Bank OZK adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 5 Analyst Projections For Bank OZK

Across the recent three months, 14 analysts have shared their insights on Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $50.36, a high estimate of $57.00, and a low estimate of $44.00. This upward trend is evident, with the current average reflecting a 5.25% increase from the previous average price target of $47.85.
<img src="https://www.benzinga.com/files/images/story/2024/1733259649_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Bank of America among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$57.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$56.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Glenn Thum</td>
<td>Phillip Securities</td>
<td>Announces</td>
<td>Accumulate</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$49.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$49.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bank of America. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Bank of America compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Bank of America's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bank of America's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BAC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bank of America analyst ratings.</a>
<h2>Get to Know Bank of America Better</h2>
Bank of America is one of the largest financial institutions in the United States, with more than $3.0 trillion in assets. It is organized into four major segments: consumer banking, global wealth and investment management, global banking, and global markets. Bank of America's consumer-facing lines of business include its network of branches and deposit-gathering operations, retail lending products, credit and debit cards, and small-business services. The company's Merrill Lynch operations provide brokerage and wealth-management services, as does its private bank. Wholesale lines of business include investment banking, corporate and commercial real estate lending, and capital markets operations. Bank of America has operations in several countries but is primarily US-focused.
<h3>Bank of America: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Bank of America's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.71% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Bank of America's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 25.17%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Bank of America's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.37%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Bank of America's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.19%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Bank of America's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.23.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Bank of America's Future

Cannabis-infused edibles producer Grön (pronounced grewn) announced the release of an exclusive flavor available only in Arizona at Curaleaf (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTCQX">CURLF</a>) locations: Prickly Pear. Inspired by the Southwest's vibrant desert landscape, the new flavor will be accessible in two product options: Prickly Pear MEGA, available in a 10-pack and Prickly Pear Sugar-Coated Pearls.
"Arizona is a key market for us, and we are thrilled to create a product that truly resonates with local tastes," stated Christine Apple, founder and CEO of Grön. "The Prickly Pear MEGAs aren't just delicious edibles—they're a celebration of Arizona's unique character and desert culture and the Prickly Pear Pearls will be a perfect addition to our lineup. We're so happy to bring this distinct experience to our Arizona customers."
Read Also: <a href="https://www.benzinga.com/24/12/42279343/nasdaq-listed-weed-stock-hiti-surges-over-21-in-the-last-two-sessions">NASDAQ-Listed Weed Stock, High Tides Surges Over 21% In Last Two Sessions</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
The new products will be exclusively available at all 16 Curaleaf dispensaries in Arizona, marking it as a unique, ongoing offering tailored for Arizona consumers.
The MEGA 10-Packs weighs in at nearly a half pound per pack containing 10 large MEGAs totaling 1,000 milligrams of THC per package. The Prickly Pear Sugar-Coated Pearls will contain 100mg of THC per package, with 10mg THC per pearl.
The Prickly Pear MEGA 10-Pack represents a unique collaboration between Grön and cannabis retail giant Curaleaf. With a balanced sweet-tart taste, the prickly pear flavor is a popular choice among Arizona consumers, who tend to enjoy more high-dose products.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42050078/curaleaf-secures-first-marijuana-research-license-in-massachusetts">Inside Grön&#8217;s Marijuana Edibles Factory: What Can We Learn About Choco-Nomics And Multi-State Expansion?</a></li>
</ul>
Courtesy photo

Cannabis

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

Grön Launches New Edibles Flavors Across Curaleaf Dispensaries In Arizona

Flora Farms, a prominent cannabis producer in Missouri, voluntarily recalled over 3,000 Zen-brand cannabis gummies last month after state regulators flagged a <a href="https://www.benzinga.com/cannabis">labeling oversight. </a>
The issue? The ingredient list omitted the specific food coloring used in the gummies, Missouri Independent <a href="https://missouriindependent.com/briefs/labeling-error-led-to-missouri-recall-of-cannabis-gummies/">reported.</a>
<h3 class="wp-block-heading">A Regulatory Reminder</h3>
According to Sami Jo Freeman, spokeswoman for Missouri's Division of Cannabis Regulation (DCR), the recall stemmed not from the food coloring itself, which is not banned, but from the omission on the ingredients list.
See Also: <a href="https://www.benzinga.com/24/12/42300451/nasdaq-listed-high-tide-under-the-magnifying-glass-key-insights-for-cannabis-investors">NASDAQ-Listed High Tide Under The Magnifying Glass: Key Insights For Cannabis Investors</a>
"Food coloring must be disclosed in the ingredient list in order to be used in a product," Freeman explained. "This helps consumers know that if they have an allergy to it, that they should not consume that product."
Only one adverse reaction was reported and the incident did not require hospitalization.
<h3 class="wp-block-heading">Cannabis&#8217; Compliance Challenges</h3>
The recall occurred despite <a href="https://www.benzinga.com/topic/missouri-cannabis">Missouri's newly implemented recreational marijuana </a>packaging and labeling rules. Since Sept. 1, manufacturers have been required to submit packaging and labels for pre-approval by the DCR before products reach dispensary shelves. 
However, this process focuses more on design compliance such as ensuring information is included and packaging is not appealing to children, rather than on verifying the accuracy of ingredient lists.
"Verification of whether information is accurate occurs through other processes, such as inspections, complaints, and investigations," Freeman clarified.
Missouri's rules mandate that cannabis packaging feature plain designs with limited colors and minimal branding. These measures aim to comply with the state's constitutional requirement that marijuana-related product packaging "shall not be made to be attractive to children."
Mark Hendren, president of Flora Farms, replied. "DCR requested that Zen labels more specifically identify the food coloring used. So that's what we have done."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42299396/the-state-of-nebraska-is-pushing-back-against-cannabis-both-locally-and-nationally">Nebraska&#8217;s Two-Front War On Cannabis</a></li>
</ul>
Cover image made with AI.

Regulations

Markets

Why This Cannabis Company Recalled Over 3,000 Gummies In Missouri

Analysts' ratings for Interactive Brokers Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $167.75, along with a high estimate of $195.00 and a low estimate of $155.00. This upward trend is apparent, with the current average reflecting a 8.31% increase from the previous average price target of $154.88.
<img src="https://www.benzinga.com/files/images/story/2024/1733259610_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Interactive Brokers Gr by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Daniel Fannon</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$155.00</td>
<td>$145.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Interactive Brokers Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Interactive Brokers Gr compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Interactive Brokers Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Interactive Brokers Gr's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IBKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Interactive Brokers Gr analyst ratings.</a>
<h2>About Interactive Brokers Gr</h2>
Interactive Brokers is an online brokerage that generates trading commissions (around 31% of net revenue) from facilitating trading in a wide range of products, including equity, options, futures, foreign exchange, bonds, mutual funds, and exchange-traded funds. Interactive Brokers also generates net interest income (about 64% of net revenue) from idle client cash and earns fees (about 6% of net revenue) from ancillary services. Principal trading and other miscellaneous activities are small (about 5% of net revenue). The firm derives about 70% of its net revenue from the US and 30% from international markets.
<h3>Interactive Brokers Gr: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Interactive Brokers Gr's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 18.1%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Interactive Brokers Gr's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 7.68%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Interactive Brokers Gr's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.56%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Interactive Brokers Gr's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.13%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Interactive Brokers Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IBKR

Peeling Back The Layers: Exploring Interactive Brokers Gr Through Analyst Insights

Global companies with at least 50% U.S. revenue exposure as Trump eyes tariffs: BofA

BeiGene (BGNE) has entered into a settlement agreement with MSN Pharmaceuticals and MSN Laboratories Private resolving patent litigation related to...

BeiGene settles litigation against generic filer of Brukinsa

China ADRs have increased to the largest share since late 2021 – GS

BeiGene (BGNE) announced that the European Commission has approved Tevimbra in combination with chemotherapy for the first-line treatment of esopha...

BeiGene announces EC approval of Tevimbra

European Commission approves products by BeiGene, GSK and Novartis

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BeiGene (BGNE – Research Report) and Teladoc (TDOC – Research Rep...

Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)

BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US

BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And U.S.

Morgan Stanley assumed coverage of BeiGene (BGNE) with an Overweight rating and $300 price target The firm sees BeiGene's Brukinsa continuing to ga...

BeiGene assumed with an Overweight at Morgan Stanley

BeiGene started at overweight at Morgan Stanley on Brukinsa market share growth

ABBV

ARGX

ATAT

BABA

BRDCY

FUJHY

HTHT

KWEB

LEGN

LNVGY

MCHI

QFIN

SVNDY

TCOM

TDOC

UPRO

ZLAB

Press Releases

BeiGene Mourns Death of Beloved Board Member Donald Glazer

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

BeiGene to Present at the Jefferies London Healthcare Conference

BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

BeiGene to Present at Upcoming Investor Conferences

European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Morgan Stanley

TD Cowen

JP Morgan

JMP Securities

Citigroup

先週の株価下落率上位10社に名を連ねたのは以下の銘柄だ。投資家はこれらの銘柄を保有しているだろうか？
<ol>
<li>Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) の株価は、同社が市場予想を下回る<a class="ticker" href="https://www.benzinga.com//node/39523397" target="_blank" rel="noopener noreferrer">第3四半期決算を発表し</a>、2024年の業績予想を引き下げたことから24.12%急落した。アナリストは、株の<a class="ticker" href="https://www.benzinga.com/quote/wba/analyst-ratings" target="_blank" rel="noopener noreferrer">株価予想を引き下げている</a>。</li>
<li>Floor &amp; Decor Holdings, Inc.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>)の株は13.41%下落し、これは5月の予定住宅販売経済指標が期待を下回ったことに対するリアクションかもしれない。</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) の株価は同社のRSVワクチン接種の効果が<a class="ticker" href="https://www.benzinga.com//node/39508239" target="_blank" rel="noopener noreferrer">50%という結果</a>から11.76%下がった。</li>
<li>Birkenstock Holding Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) の株は同社が1千4百万株までの株式オファリングを<a href="https://www.benzinga.com//node/39467369" target="_blank" rel="noopener noreferrer">株主買い戻しによって行う</a>と発表したことで10.86%下落した。</li>
<li>BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>) の株は9.70%下落した。</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) の株価は同社が同社の<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">決算予想を下方修正した</a>後、9.19%下がった。</li>
<li>JD.Com, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) の株価は、米国が中国企業への<a class="ticker" href="https://www.benzinga.com//node/39521291" target="_blank" rel="noopener noreferrer">投資を抑制する規則を発表した</a>ことで8.89%下落した。</li>
<li>Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) の株価は8.02%急落した</li>
<li>International Paper Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>) の株価はSuzano SA（NYSE:SUZ）が同社の<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">買収取引</a>を進展させないと発表したことに伴い、7.98%下落した。</li>
<li>Micron Technology Inc.の（NASDAQ:MU）株は、第3四半期の決算と第4四半期の見通し<a href="https://www.benzinga.com//node/39520174" target="_blank" rel="noreferrer noopener">を発表したことを受け、先週7.62%急落</a>した。</li>
</ol>

Comments

BeiGene

ニュース

最新ニュース BeiGene (NASDAQ:BGNE) 株価情報

月曜日, 7 01, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル